Media Contact:
Lorraine Marshall Wright
lmwright@holaira.com

Holaira Hosts Educational Symposium on Targeted Lung Denervation (TLD) in Obstructive Lung Disease at ERS

London, Sept. 5, 2016Holaira, Inc., a developer of medical devices to treat obstructive lung diseases, announced it will host an educational symposium on the use of Targeted Lung Denervation* (TLD) in obstructive lung disease during the European Respiratory Society International Congress, Sept. 6, in London.

First COPD Patient Treated in Holaira’s Sham Controlled Trial of Targeted Lung Denervation

Minneapolis, Minn., Aug. 3, 2016 – Holaira, a developer of medical devices to treat obstructive lung diseases, announced the initiation of treatments in the AIRFLOW-2 Clinical Trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD) in a procedure called Targeted Lung Denervation* (TLD). Under the direction of principal investigator, Christophe Pison, M.D., Ph.D., the first patient was treated at the Grenoble University Hospital Centre (CHUG) in Grenoble, France, using the Holaira™ Lung Denervation System.

Holaira to Host Symposium at ERS Congress on Targeted Lung Denervation (TLD) for Patients with COPD

Amsterdam, Sept. 28, 2015 – Holaira, Inc., a developer of medical devices to treat obstructive lung diseases,announced it will host a mini-symposium on Targeted Lung Denervation* (TLD) in patients with moderate to severe COPD, at the European Respiratory Society International Congress, Sept. 28. The program will be co-chaired by Professors Felix Herth, M.D., Ph.D., FCCP, Chairman, Division of Pulmonology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, and Alvar Agustí, M.D., Ph.D., Director of the Thorax Institute at Hospital Clinic in Barcelona. Four scientific experts will present their findings on topics including: Cholinergic Pathways and the Need for New Therapies in COPD; Mechanism of Action and the Holaira™ Lung Denervation System; Long-term Safety and Efficacy of TLD in 37 COPD Patients, and Early Experience from the AIRFLOW-1 Clinical Study.

Holaira Announces First Patient Treatment in Randomized Study of Targeted Lung Denervation for COPD

Minneapolis, Minn., Oct. 7, 2014 – Holaira, Inc., a developer of medical devices to treat obstructive lung diseases, today announced the initiation of treatments in the AIRFLOW-1 Clinical Study for patients with moderate to severe chronic obstructive pulmonary disease (COPD) in a procedure called Targeted Lung Denervation* (TLD). Using the Holaira™ Lung Denervation System, the first patient was treated at one of the premier centers for pulmonology, Otto Wagner Spital in Vienna, Austria. Arschang Valipour, M.D., Ph.D., FCCP and Group Leader at the Ludwig-Boltzmann Institute for COPD and Respiratory Epidemiology in the Department of Respiratory and Critical Care Medicine at Otto Wagner Spital, performed the first treatment.

“The data from the evaluation of TLD in COPD patients using Holaira’s Lung Denervation system is very promising, as the procedure was well tolerated by patients and it demonstrates feasibility and safety. Because COPD is a progressive disease that affects millions of people and places a significant financial burden on the system, it is imperative that we find alternative methods of treatment that may provide lasting, whole lung improvement.”

Felix Herth, M.D., Ph.D., FCCP